Carotegrast Methyl in Ulcerative Colitis

Inclusion Criteria:

• Patients diagnosed with UC based on endoscopic and histological findings

• Patients with clinically and endoscopically moderate UC who were eligible foroutpatient treatment (however, patients in clinical remission or with mild clinicalactivity but endoscopically moderate UC were also considered eligible as anexception)

• Patients who exhibited an inadequate response to or intolerance of 5-ASAformulations (including topical agents) or budesonide formulations (includingtopical agents)

• Patients who provided informed consent for endoscopic examinations at the start oftreatment and during the treatment period

• Patients who agreed to blood sampling and fecal biomarker tests

Exclusion Criteria:

• Patients with severe disease on endoscopy (presumed ineffective due to the drug'scharacteristics)

• Patients currently using biologics, JAK inhibitors, thiopurines, or calcineurininhibitors (tacrolimus or cyclosporine)

• Patients with a history of malignancy

• Patients with severe hepatic dysfunction

• Pregnant women or those planning pregnancy

• Patients with acute severe conditions, such as toxic megacolon, sepsis, peritonitis,or infectious colitis